|
BoomRay focuses on radioligand therapies for precision oncology, spanning candidate discovery and clinical translation activities.
|
 |
|
Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.
|
|
|
The facility is positioned to supply therapies for clinical and commercial use in 2027.
|
|
|
Backing for the approval comes from data in NewAmsterdam’s clinical development programme, including Phase III trials.
|
|
|
Outlining a five-year biomedical plan, China wants to expand its global role beyond just pipeline innovation.
|
|
